SEC Form 4 · accession 0001349929-15-000038
CANCER GENETICS, INC · CGIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
John Pappajohn
Director
Period of report
Aug 26, 2015
Accepted (ET)
Aug 27, 2015 · 5:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001349929
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF1 | Aug 26, 2015 | P | 2,500 | $8.9744 | A | 1,516,789 | D | |
| Common Stock, par value $0.0001 per shareF2 | Aug 27, 2015 | P | 2,500 | $10.2496 | A | 1,519,289 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F11. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.920 to $9.00, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes(1)and(2)to this Form 4.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.24 to $10.25, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.